Anthony Manning Acquires Shares of Monte Rosa Therapeutics
Anthony Manning purchased 10,000 shares of Monte Rosa Therapeutics at $4.16 each.
Key Points
- Anthony Manning acquired 10,000 shares of Monte Rosa Therapeutics, Inc. (GLUE) on June 29, 2026, for $41,600.
- Monte Rosa shares traded near $24.20 on Wednesday with a market cap of approximately $2.04 billion.
- Analysts maintain a positive outlook on Monte Rosa, with recent buy ratings and a target mean price of $32.33.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Anthony Manning, a notable figure, recently acquired 10,000 shares of Monte Rosa Therapeutics, Inc. (NasdaqGS: GLUE) on June 29, 2026. The shares were purchased at an average price of $4.16, amounting to a total transaction value of $41,600. This insider buying activity was not part of a pre-planned trading program.
Insider Buying and Selling at Monte Rosa Therapeutics, Inc.
In addition to Anthony Manning's purchase, there were other notable transactions at Monte Rosa on the same date. Filip Janku, the Chief Medical Officer, was involved in multiple transactions, including a planned sale of 6,000 shares at $22.95 and an unplanned purchase of 6,000 shares at $7.56.
Other Institutional Activity in Monte Rosa Therapeutics
Several institutional investors have also been active in Monte Rosa Therapeutics. Price T Rowe Associates Inc /MD/ increased its holdings by 1,601,284 shares, bringing its total to 6,720,188 shares valued at approximately $110.5 million, marking a 31.3% increase. Versant Venture Management, LLC, added 1,978,873 shares, ending with 6,361,560 shares worth around $104.6 million, a 45.2% increase. BlackRock, Inc. also grew its position by 1,456,523 shares, totaling 5,637,684 shares valued at $92.7 million, reflecting a 34.8% increase.
Monte Rosa Therapeutics, Inc. Stock Up 73.6%
On Wednesday, shares of Monte Rosa Therapeutics traded near $24.20. The company has a market capitalization of about $2.04 billion. It is currently not profitable, with a forward P/E ratio of -13.34. The stock has seen a 52-week low of $4.12 and a high of $25.77. Its 50-day moving average is $19.09, while the 200-day moving average stands at $16.34. Monte Rosa maintains a strong liquidity position with a current ratio of 9.54 and a quick ratio of 9.44.
$GLUE stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts are optimistic about Monte Rosa Therapeutics' prospects. On June 30, 2026, Guggenheim maintained its 'buy' rating with a price target of $35.00. Earlier, JP Morgan also maintained a 'buy' rating with a target of $31.00 on May 11, 2026. Overall, the consensus among six analysts is a 'buy' rating, with a target mean price of $32.33.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts. It focuses on developing small molecule precision medicines that leverage the body's natural processes to selectively degrade harmful proteins. The company is working on several programs, including treatments for MYC-driven tumors, autoimmune diseases, and various cancers. Founded in 2019, Monte Rosa employs 187 people and is led by CEO Dr. Markus Warmuth.
Bottom Line
Anthony Manning's recent purchase of Monte Rosa Therapeutics shares highlights ongoing interest in the company's potential. While the stock has experienced significant price fluctuations, analysts remain optimistic with strong buy ratings and a favorable target price. Investors often watch insider transactions like these for potential insights into a company's prospects.
Get Monte Rosa Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GLUE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.